LABSTYLE INNOVATIONS TO PRESENT AT ONEMEDFORUM 2013 NEW YORK
Webcast of company presentation begins at 10:20 a.m. Eastern time on June 27
Jun 20, 2013
RAMAT GAN, Israel (June 20, 2013) – LabStyle Innovations Corp. (OTCQB: DRIO), an emerging leader in mobile health (mHealth) and developer of the Dario™ smartphone-based diabetes management system, announces that Dr. Oren Fuerst, LabStyle’s Chairman and Chief Executive Officer, will be participating in the OneMedForum 2013 New York conference being held June 26-27 at the Metropolitan Club in New York City. The LabStyle presentation will begin at 10:20 a.m. Eastern time on June 27, and a webcast will be available in the Investors section of www.mydario.com and at http://onemedplace.com/forum/webcast/.
In addition to the company presentation, Dr. Fuerst will participate in a breakout session immediately following his presentation, as well as one-on-one meetings at the conference. Investors interested in attending the conference or arranging a meeting with Dr. Fuerst should visit www.onemedforum.com.
About LabStyle Innovations
LabStyle Innovations Corp. has developed and is commercializing a patent-pending technology that seeks to bring laboratory-testing capabilities to consumers in a distinctive, easy-to-use and affordable way through the use of smartphones such as iPhones and Androids, and other mobile devices. LabStyle’s initial product is Dario™, an integrated medical device and software system addressing the market for patient self-monitoring of blood glucose (SMBG) products, which is estimated to exceed $10 billion worldwide. Dario is a comprehensive, patent-pending system that combines an all-in-one medical device consisting of an integrated lancet (to obtain a blood sample), a device-specific disposable test strip cartridge and a smartphone-driven glucose reader adaptor, with a smartphone app and cloud-based data services. LabStyle is pursuing patent applications in multiple jurisdictions covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the Company) related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, those related to the outcome of regulatory review of the Company's products and the Company's anticipations for commercial launch of its products) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
LabStyle Innovations Corp.
Oren Fuerst, Chairman/CEO